Allon Appoints Biotech Leader to its Board of Directors
In May 2010 Aldridge joined Xenome, a pain company focused on the development of peptide-based therapeutics with a product in late-stage clinical trials. From 2003 to 2008, he led Peplin, Inc., a public company that grew under his leadership into a global dermatology company with two skin cancer products in late-stage clinical trials. Peplin was sold to LEO Pharma A/S, a European dermatology company, for US$287.5 million in cash. Previous to his leadership at Peplin, Aldridge had a successful investment banking career in Australia, New York, and London.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.